An illustration dated January 16, 2022, shows a vial labeled as “Novavax V COVID-19 Vaccine.”
Photo credit: Dado Ruvic | Reuters
The FDA has granted emergency use authorization for Novavax’s updated protein-based Covid vaccine for individuals aged 12 and above. This approval sets the stage for Novavax’s vaccine to enter the market alongside Pfizer and Moderna’s offerings during the upcoming fall and winter seasons.
Specifically designed to combat the highly transmissible omicron subvariant JN.1, Novavax’s vaccine is tailored to address the evolving landscape of Covid variants. Despite the challenges posed by rapidly mutating strains, Novavax’s vaccine demonstrates efficacy against prevalent descendants of JN.1 in the U.S., such as KP.2.3, KP.3, KP.3.1.1, and LB.1.
Novavax’s protein-based vaccine technology, while not as easily adaptable to new strains, remains a crucial player in the ongoing battle against Covid.
“Our latest vaccine iteration focuses on JN.1, the original strain that continues to evolve,” a spokesperson from Novavax stated.
2024-08-30 14:50:23
Post sourced from www.cnbc.com